Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT

Purpose: Current delineation of the gross tumor volume (GTV) in esophageal cancer relies on computed tomography (CT) and combination with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET). There is increasing interest in integrating magnetic resonance imaging (MRI) in radiation treatme...

Full description

Bibliographic Details
Main Authors: Sophie E. Vollenbrock, MD, Marlies E. Nowee, MD, PhD, Francine E.M. Voncken, MD, Alexis N.T.J. Kotte, PhD, Lucas Goense, MD, PhD, Peter S.N. van Rossum, MD, PhD, Astrid L.H.M.W. van Lier, PhD, Stijn W. Heijmink, MD, PhD, Annemarieke Bartels-Rutten, MD, PhD, Frank J. Wessels, MD, Berthe M.P. Aleman, MD, PhD, Luc Dewit, MD, PhD, Linda G.W. Kerkmeijer, MD, PhD, Edwin P.M. Jansen, MD, PhD, Martijn Intven, MD, PhD, Irene M. Lips, MD, PhD, Gert J. Meijer, PhD, Jasper Nijkamp, PhD
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109419300521
id doaj-7c3a297a718342fba7604b7730874f72
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Sophie E. Vollenbrock, MD
Marlies E. Nowee, MD, PhD
Francine E.M. Voncken, MD
Alexis N.T.J. Kotte, PhD
Lucas Goense, MD, PhD
Peter S.N. van Rossum, MD, PhD
Astrid L.H.M.W. van Lier, PhD
Stijn W. Heijmink, MD, PhD
Annemarieke Bartels-Rutten, MD, PhD
Frank J. Wessels, MD
Berthe M.P. Aleman, MD, PhD
Luc Dewit, MD, PhD
Linda G.W. Kerkmeijer, MD, PhD
Edwin P.M. Jansen, MD, PhD
Martijn Intven, MD, PhD
Irene M. Lips, MD, PhD
Gert J. Meijer, PhD
Jasper Nijkamp, PhD
spellingShingle Sophie E. Vollenbrock, MD
Marlies E. Nowee, MD, PhD
Francine E.M. Voncken, MD
Alexis N.T.J. Kotte, PhD
Lucas Goense, MD, PhD
Peter S.N. van Rossum, MD, PhD
Astrid L.H.M.W. van Lier, PhD
Stijn W. Heijmink, MD, PhD
Annemarieke Bartels-Rutten, MD, PhD
Frank J. Wessels, MD
Berthe M.P. Aleman, MD, PhD
Luc Dewit, MD, PhD
Linda G.W. Kerkmeijer, MD, PhD
Edwin P.M. Jansen, MD, PhD
Martijn Intven, MD, PhD
Irene M. Lips, MD, PhD
Gert J. Meijer, PhD
Jasper Nijkamp, PhD
Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT
Advances in Radiation Oncology
author_facet Sophie E. Vollenbrock, MD
Marlies E. Nowee, MD, PhD
Francine E.M. Voncken, MD
Alexis N.T.J. Kotte, PhD
Lucas Goense, MD, PhD
Peter S.N. van Rossum, MD, PhD
Astrid L.H.M.W. van Lier, PhD
Stijn W. Heijmink, MD, PhD
Annemarieke Bartels-Rutten, MD, PhD
Frank J. Wessels, MD
Berthe M.P. Aleman, MD, PhD
Luc Dewit, MD, PhD
Linda G.W. Kerkmeijer, MD, PhD
Edwin P.M. Jansen, MD, PhD
Martijn Intven, MD, PhD
Irene M. Lips, MD, PhD
Gert J. Meijer, PhD
Jasper Nijkamp, PhD
author_sort Sophie E. Vollenbrock, MD
title Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT
title_short Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT
title_full Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT
title_fullStr Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT
title_full_unstemmed Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT
title_sort gross tumor delineation in esophageal cancer on mri compared with 18f-fdg-pet/ct
publisher Elsevier
series Advances in Radiation Oncology
issn 2452-1094
publishDate 2019-10-01
description Purpose: Current delineation of the gross tumor volume (GTV) in esophageal cancer relies on computed tomography (CT) and combination with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET). There is increasing interest in integrating magnetic resonance imaging (MRI) in radiation treatment, which can potentially obviate CT- or FDG-PET/CT–based delineation. The aim of this study is to evaluate the feasibility of target delineation on T2-weighted (T2W) MRI and T2W including diffusion-weighted MRI (T2W + DW-MRI) compared with current-practice FDG-PET/CT. Methods: Ten observers delineated primary esophageal tumor GTVs of 6 patients on FDG-PET/CT, T2W-MRI, and T2W + DW-MRI. GTVs, generalized conformity indices, in-slice delineation variation (root mean square), and standard deviations in the position of the most cranial and caudal delineated slice were calculated. Results: Delineations on MRI showed smaller GTVs compared with FDG-PET/CT–based delineations. The main variation was seen at the cranial and caudal border. No differences were observed in conformity indices (FDG-PET/CT, 0.68; T2W-MRI, 0.66; T2W + DW-MRI, 0.68) and in-slice variation (root mean square, 0.13 cm on FDG-PET/CT; 0.10 cm on T2W-MRI; 0.14 cm on T2W + DW-MRI). In the 2 tumors involving the gastroesophageal junction, addition of DW-MRI to T2W-MRI significantly decreased caudal border variation. Conclusions: MRI-based target delineation of the esophageal tumor is feasible with interobserver variability comparable to that with FDG-PET/CT, despite limited experience with delineation on MRI. Most variation was seen at cranial-caudal borders, and addition of DW-MRI to T2W-MRI may reduce caudal delineation variation of gastroesophageal junction tumors.
url http://www.sciencedirect.com/science/article/pii/S2452109419300521
work_keys_str_mv AT sophieevollenbrockmd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT marliesenoweemdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT francineemvonckenmd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT alexisntjkottephd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT lucasgoensemdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT petersnvanrossummdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT astridlhmwvanlierphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT stijnwheijminkmdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT annemariekebartelsruttenmdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT frankjwesselsmd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT berthempalemanmdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT lucdewitmdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT lindagwkerkmeijermdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT edwinpmjansenmdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT martijnintvenmdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT irenemlipsmdphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT gertjmeijerphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
AT jaspernijkampphd grosstumordelineationinesophagealcanceronmricomparedwith18ffdgpetct
_version_ 1725880150866788352
spelling doaj-7c3a297a718342fba7604b7730874f722020-11-24T21:51:09ZengElsevierAdvances in Radiation Oncology2452-10942019-10-0144596604Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CTSophie E. Vollenbrock, MD0Marlies E. Nowee, MD, PhD1Francine E.M. Voncken, MD2Alexis N.T.J. Kotte, PhD3Lucas Goense, MD, PhD4Peter S.N. van Rossum, MD, PhD5Astrid L.H.M.W. van Lier, PhD6Stijn W. Heijmink, MD, PhD7Annemarieke Bartels-Rutten, MD, PhD8Frank J. Wessels, MD9Berthe M.P. Aleman, MD, PhD10Luc Dewit, MD, PhD11Linda G.W. Kerkmeijer, MD, PhD12Edwin P.M. Jansen, MD, PhD13Martijn Intven, MD, PhD14Irene M. Lips, MD, PhD15Gert J. Meijer, PhD16Jasper Nijkamp, PhD17Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Surgery, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Corresponding author. Departments of Surgery and Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.Purpose: Current delineation of the gross tumor volume (GTV) in esophageal cancer relies on computed tomography (CT) and combination with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET). There is increasing interest in integrating magnetic resonance imaging (MRI) in radiation treatment, which can potentially obviate CT- or FDG-PET/CT–based delineation. The aim of this study is to evaluate the feasibility of target delineation on T2-weighted (T2W) MRI and T2W including diffusion-weighted MRI (T2W + DW-MRI) compared with current-practice FDG-PET/CT. Methods: Ten observers delineated primary esophageal tumor GTVs of 6 patients on FDG-PET/CT, T2W-MRI, and T2W + DW-MRI. GTVs, generalized conformity indices, in-slice delineation variation (root mean square), and standard deviations in the position of the most cranial and caudal delineated slice were calculated. Results: Delineations on MRI showed smaller GTVs compared with FDG-PET/CT–based delineations. The main variation was seen at the cranial and caudal border. No differences were observed in conformity indices (FDG-PET/CT, 0.68; T2W-MRI, 0.66; T2W + DW-MRI, 0.68) and in-slice variation (root mean square, 0.13 cm on FDG-PET/CT; 0.10 cm on T2W-MRI; 0.14 cm on T2W + DW-MRI). In the 2 tumors involving the gastroesophageal junction, addition of DW-MRI to T2W-MRI significantly decreased caudal border variation. Conclusions: MRI-based target delineation of the esophageal tumor is feasible with interobserver variability comparable to that with FDG-PET/CT, despite limited experience with delineation on MRI. Most variation was seen at cranial-caudal borders, and addition of DW-MRI to T2W-MRI may reduce caudal delineation variation of gastroesophageal junction tumors.http://www.sciencedirect.com/science/article/pii/S2452109419300521